Half-year highlights: GTG, Ambri, Iatia
02 March, 2004 by Melissa TrudingerGenetic Technologies' (ASX: GTG) increased loss, as reported in the company's half-year results last week, was in part due to changes in accounting required for the company's upcoming listing on the US Nasdaq market through the level 2 ADR program, executive chairman Dr Mervyn Jacobson said today.
Deutsche VP weighs in on M&A debate
02 March, 2004 by Melissa TrudingerThe vice-president at Deutsche Bank Global Corporate Finance in Australia has called on Australian biotech companies to seriously consider collaborations and M&A activity with other biotechs if they want to be viable.
ARC moves to end grant confusion
01 March, 2004 by Melissa TrudingerChanges to the wording of the Australian Research Council's discovery grant eligibility criteria have left scientists at medical research institutes believing they are no longer eligible to apply for grants from the organisation.
Feds, industry team up on science action agenda
27 February, 2004 by Melissa TrudingerThe federal government has teamed up with industry group Science Industry Australia (SIA) to create a new action agenda.
WA researchers develop new MRI method
26 February, 2004 by Melissa TrudingerResearchers at the University of Western Australia have developed a novel method for detecting iron overload diseases using magnetic resonance imaging (MRI).
Ethics, research needs must be balanced: Cotton
24 February, 2004 by Melissa TrudingerAn Australian geneticist has called for better balancing of ethical concerns with researchers' needs when it comes to developing guidelines for the collection of human genetic and genomic information into databases for research purposes.
Medica highlights successes in half-year results
17 February, 2004 by Graeme O'NeillBrisbane-based Pooled Development Fund Medica Holdings (ASX:MCA) is feeling no pain despite reporting a AUD$2.4 million loss in the six months to December 31 last year.
Victorian consortium invests $2 m into Melbourne Uni spin-off
13 February, 2004 by Melissa TrudingerMelbourne University spin-off Cryptopharma has received a boost with AUD$2 million in funding from a Victorian consortium of investors led by GBS Venture Partners, Biocomm and Uniseed.
CogState makes ASX debut
13 February, 2004 by Melissa TrudingerMelbourne company CogState has made its debut on the ASX, after raising AUD$7 million in its IPO.
US giant LabCorp signs up for GTG license
09 February, 2004 by Melissa TrudingerMelbourne company Genetic Technologies (ASX:GTG) has added another large US company to its tally, with Laboratory Corporation of America Holdings -- otherwise known as LabCorp -- becoming the latest to license the company's non-coding DNA mapping and analysis patents.
Vaccine firm names new CEO
06 February, 2004 by Graeme O'NeillCanberra vaccine developer Vaxine has appointed Ted Stapinski, a 20-year veteran of Australia's space industry, as its new CEO.
AusBiotech to strengthen NZ ties
05 February, 2004 by Melissa TrudingerIndustry body AusBiotech and its New Zealand counterpart, NZBio, are planning to work together on a number of projects this year to strengthen ties between the two countries and promote the capabilities of the region.
HECS fee cut no windfall for science, says expert
22 January, 2004 by Graeme O'NeillMacquarie University's decision to waive or reduce Higher Education Contribution Scheme (HECS) fees for some science and technology subjects is likely to have little impact on students' choices about where and what they study, according to a Melbourne expert on education policy.
BresaGen goes into voluntary administration
20 January, 2004 by Melissa TrudingerAustralian biotechnology veteran BresaGen (ASX:BGN) has gone into voluntary administration.
Bionomics reports healthy bank balance
20 January, 2004 by Graeme O'NeillAdelaide biotech Bionomics (ASX:BNO) has reported that it had nearly AUD$5 million in the bank at the end of the December 2003 quarter, giving it enough cash for at least two years at its current burn rate.
